

*Sub 62*  
*Rule 1.126*  
<sup>60</sup>  
61. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed by cotransfecting an Sf-9 insect cell with recombinant baculovirus DNA and wild-type baculovirus DNA.

*Sub D*  
<sup>61</sup>  
62. (NEW) A eukaryotic virus pseudo-nucleocapsid comprising:  
  
at least a portion of a viral capsid polypeptide; and  
  
a tRNA polynucleotide, wherein said viral capsid polypeptide and polynucleotide together participate in formation of a generally spheroid pseudo-nucleocapsid.

<sup>62</sup>  
63. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said eukaryotic virus pseudo-nucleocapsid is formed in vitro.

<sup>63</sup>  
64. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said viral capsid polypeptide comprises a recombinant polypeptide.

<sup>64</sup>  
65. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said viral capsid polypeptide comprises SEQ ID NO.: 1.

*B cont*  
<sup>65</sup>  
66. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said polynucleotide comprises a portion of a hepatitis C virus genome.

# RESTRICTION

Claims 1 through 48 are subject to a restriction requirement under 35 U.S.C. §121. The Action identifies a restriction to twelve groups of inventions. Applicants hereby elect Group II, claims 5 through 7, with traverse, for continued prosecution. Claims 1-4 and 8-48 have been cancelled.

New claims 49-66 depend from and/or are drawn to the elected group. Support in the specification for the added claims may be found in the claims as filed and throughout the specification.

This Amendment does not increase the number of independent claims, does not increase the total number of claims, and does not present any multiple independent claims. Accordingly, no fee based on the number or type of claims is currently due. However, if a fee is due, please charge this fee to our Deposit Account No. 07-0153.

CONCLUSION

Applicants elect Group II, claims 5-7, with traverse for continued prosecution. New claims 49-66 depend from and/or are drawn to the elected group. Favorable consideration and allowance of the application is therefore respectfully requested. If the Examiner has any questions or comments, or if further clarification is required, it is requested that the Examiner contact the undersigned at the telephone number listed below.

Respectfully submitted,




Edwin S. Flores  
Reg. No. 38,453

Dated: August 23, 2002

ATTORNEY FOR APPLICANTS

GARDERE WYNNE SEWELL LLP  
3000 Thanksgiving Tower  
1601 Elm Street  
Dallas, Texas 75201-4761  
(214) 999-4559  
(214) 999-3559 (Fax)



Attorney Docket No.: 122144-1008

Re Application: Stanley J. Watowich, Meghan Kunkel and Marta Lorinczi

Serial No. 09/713,687

Filed: November 15, 2000

For: VIRAL PSEUDO-CAPSIDS INCLUDING ASSEMBLY AGONISTS  
AND ANTAGONISTS

PATENT  
RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

**Marked-up Version of the New Claims**

49. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said polynucleotide comprises a tRNA.

50. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said eukaryotic virus pseudo-nucleocapsid is formed in an in vitro array.

51. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said viral capsid polypeptide comprises a recombinant polypeptide.

52. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said viral capsid polypeptide comprises a recombinant polypeptide that is functionally homologous to a HCV core protein sequence.

53. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said viral capsid polypeptide comprises SEQ ID NO.: 1.

54. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said viral capsid polypeptide comprises truncations of SEQ ID NO.:1.

55. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said polynucleotide comprises a hepatitis C virus genome.

57. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed in an insect cell host.

58. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed in an Sf-9 insect cell.

59. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed in a mammalian cell host.

60. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed in a yeast cell host.

61. (NEW) The virus pseudo-nucleocapsid of claim 5, wherein said virus pseudo-nucleocapsid is formed by cotransfecting an Sf-9 insect cell with recombinant baculovirus DNA and wild-type baculovirus DNA.

62. (NEW) A eukaryotic virus pseudo-nucleocapsid comprising:

at least a portion of a viral capsid polypeptide; and

a tRNA polynucleotide, wherein said viral capsid polypeptide and polynucleotide together participate in formation of a generally spheroid pseudo-nucleocapsid.

63. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said eukaryotic virus pseudo-nucleocapsid is formed in vitro.

64. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said viral capsid polypeptide comprises a recombinant polypeptide.

65. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said viral capsid polypeptide comprises SEQ ID NO.: 1.

66. (NEW) The virus pseudo-nucleocapsid of claim 62, wherein said polynucleotide comprises a portion of a hepatitis C virus genome.